Asian J Psychiatr 2017 Dec 14;30:230-231. Epub 2017 Jul 14.
NIMHANS, Bengaluru, India; Professor of Psychiatry and I/C Head of Psychiatric Rehabilitation Services, National Institute of Mental Health & Neurosciences (NIMHANS), Bengaluru 560029, India; NIMHANS, Bengaluru, India. Electronic address:
Download full-text PDF
Aust N Z J Psychiatry 1999 Oct;33(5):650-9
Neuropsychiatric Institute, The Prince of Wales Hospital, Randwick, New South Wales, Australia.
Objective: Neuroleptic malignant syndrome (NMS) is a potentially lethal adverse effect of neuroleptic medication, with no satisfactory treatment currently available. Electroconvulsive therapy (ECT) has been anecdotally reported to be effective in its treatment. We review 45 published case reports of ECT for NMS and describe nine new cases, to examine its effectiveness, the likelihood of adverse reactions, and the theoretical implications of such treatment. Read More
Convuls Ther 1993 ;9(3):198-204
Eitanim Psychiatric Hospital and Hebrew University Hadassah Medical School, Jerusalem, Israel.
The necessity of neuroleptic rechallenge in patients who have experienced neuroleptic malignant syndrome (NMS) has been discussed in recent articles. Electroconvulsive therapy (ECT) has been proposed as an alternative treatment to neuroleptics. In cases where ECT fails, neuroleptic rechallenge remains the only alternative. Read More
Int Clin Psychopharmacol 2015 Mar;30(2):115-7
aHospital Benito Menni CASM, Dr Antoni Pujadas bFIDMAG Germanes Hospitalàries Research Foundation, CIBERSAM, Barcelona, Spain.
Malign neuroleptic syndrome is a potentially life-threatening condition that is normally treated with electroconvulsive therapy (ECT). In this case report, we discuss a severely agitated and catatonic bipolar I patient who developed a neuroleptic malignant syndrome and did not improve with benzodiazepines and ECT. On the basis of anecdotal reports of the positive effects of antihistamines in psychosis and ECT, we treated our case with a combination of two antihistamines, hydroxyzine and dexclorfeniramine maleate, and ECT, which improved the clinical picture to the point of clinical remission. Read More
J Clin Psychiatry 1986 Jan;47(1):42-3
A patient with the neuroleptic malignant syndrome had a cardiac arrest after the administration of modified ECT. After the syndrome resolved, ECT was given without problems. These results suggest ECT is risky during but not after the neuroleptic malignant syndrome. Read More